SCHEMBL1667797

SCHEMBL1667797

CCOC(=O)Oc1ccccc1C=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HTT P42858 2/20 0.52
HPGD P15428 2/20 0.52
PTGDR2 Q9Y5Y4 1/20 0.51
LMNA P02545 6/20 0.49
MAPT P10636 4/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
PLIN1 O60240 1/20 0.49
POLB P06746 1/20 0.49
PLIN5 Q00G26 1/20 0.49
ABHD5 Q8WTS1 1/20 0.49
NPSR1 Q6W5P4 3/20 0.46
SRC P12931 1/20 0.46
USP2 O75604 1/20 0.46
PLA2G1B P04054 1/20 0.45
ATG4B Q9Y4P1 1/20 0.45
TYMS P04818 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7541864 0.87 LMNA (0.47) ALDH1A1SMN1; SMN2HTTHPGDPTGDR2
SCHEMBL8516383 0.85 TSHR (0.52) ALDH1A1HPGDLMNAMAPTKMT2A
SCHEMBL1979004 0.84 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2HTTHPGDPTGDR2
SCHEMBL1006065 0.83 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2HTTHPGDPTGDR2
SCHEMBL25298413 0.82 PTGDR2 (0.47) ALDH1A1SMN1; SMN2HTTHPGDPTGDR2
SCHEMBL11585516 0.82 KDM4E (0.43) ALDH1A1SMN1; SMN2HTTHPGDLMNA
SCHEMBL11585512 0.82 KDM4E (0.43) ALDH1A1SMN1; SMN2HTTHPGDLMNA
SCHEMBL1665865 0.81 MAPT (0.46) ALDH1A1SMN1; SMN2HPGDLMNAMAPT
SCHEMBL1598707 0.80 TDP1 (0.51) ALDH1A1SMN1; SMN2HTTLMNAMAPT
SCHEMBL1960366 0.80 TYMS (0.51) ALDH1A1LMNAMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509944-A1 NOVEL PEROXIDE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE Galderma Research & Development (FR) 2012-10-17 EP claimed
US-10912768-B2 Compounds and methods for treating influenza ROMARK LABORATORIES L.C. (US) 2021-02-09 US disclosed
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA ROMARK LABORATORIES L.C. (US) 2019-10-10 US disclosed
EP-2493905-B1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT CO LLC (PR) 2016-11-30 EP disclosed
US-8822435-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-09-02 US disclosed
US-20140194389-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2014-07-10 US disclosed
US-8710215-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2014-04-29 US disclosed
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2013-02-07 US disclosed
US-8314081-B2 Bisphosphonate compounds WARNER CHILCOTT COMPANY, LLC (US) 2012-11-20 US disclosed
EP-2509944-A1 NOVEL PEROXIDE DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE IN HUMAN MEDICINE AND IN COSMETICS FOR THE TREATMENT OR PREVENTION OF ACNE Galderma Research & Development (FR) 2012-10-17 EP disclosed
EP-2493905-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS Warner Chilcott Company, LLC (PR) 2012-09-05 EP disclosed
WO-2011056589-A1 BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS WARNER CHILCOTT COMPANY, LLC (US) 2011-05-12 WO disclosed
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS WARNER CHILCOTT COMPANY, LLC (US) 2011-04-28 US disclosed
CN-87103809-A The method for making of naphthane and indan derivative 1987-12-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10912768-B2 Compounds and methods for treating influenza HIF1AN, HAVCR2, NEU1 ALDH1A1 77/4885SMN1; SMN2 4684/4885HTT 3110/4885
US-20190307730-A1 COMPOUNDS AND METHODS FOR TREATING INFLUENZA HIF1AN, HAVCR2, NEU1 ALDH1A1 77/4885SMN1; SMN2 4684/4885HTT 3110/4885
US-20140194389-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN ALDH1A1 2404/4885SMN1; SMN2 2670/4885HTT 4484/4885
US-20110098251-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN ALDH1A1 2404/4885SMN1; SMN2 2670/4885HTT 4484/4885
US-20130035482-A1 BISPHOSPHONATE COMPOUNDS BPGM, PPIP5K2, PTEN ALDH1A1 2404/4885SMN1; SMN2 2670/4885HTT 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.